$-N(R^5)C(=O)R^5$;

$-N(R^5)C(=O)-*$;

$-N(R^5)C(=O)N(R^5)_2$;

$-N(R^5)C(=O)N(R^5)-*$;

$-N(R^5)CO_2R^5$;

$-NR^5C(=NR^{5a})N(R^5)_2$;

$-NR^5C(=NR^{5a})N(R^5)-*$;

$-NR^5C(=NR^{5a})R^5$;

$-N(R^5)-(C_2\text{-}C_5$ heteroaryl);

$-O-(C_1\text{-}C_{12}$ alkyl);

$-O-(C_1\text{-}C_{12}$ alkyldiyl$)-N(R^5)_2$;

$-O-(C_1\text{-}C_{12}$ alkyldiyl$)-N(R^5)-*$;

$-S(=O)_2-(C_2\text{-}C_{20}$ heterocyclyldiyl$)-*$;

$-S(=O)_2-(C_2\text{-}C_{20}$ heterocyclyldiyl$)-(C_1\text{-}C_{12}$ alkyldiyl$)-N(R^5)_2$;

$-S(=O)_2-(C_2\text{-}C_{20}$ heterocyclyldiyl$)-(C_1\text{-}C_{12}$ alkyldiyl$)-NR^5-*$; and

$-S(=O)_2-(C_2\text{-}C_{20}$ heterocyclyldiyl$)-(C_1\text{-}C_{12}$ alkyldiyl$)-OH$;

or R^2 and R^3 together form a 5- or 6-membered heterocyclyl ring;

X^1, X^2, X^3, and X^4 are independently selected from the group consisting of a bond, C(=O), $C(=O)N(R^5)$, O, $N(R^5)$, S, $S(O)_2$, and $S(O)_2N(R^5)$;

R^5 is selected from the group consisting of H, $C_6\text{-}C_{20}$ aryl, $C_6\text{-}C_{20}$ aryldiyl, $C_1\text{-}C_{12}$ alkyl, and $C_1\text{-}C_{12}$ alkyldiyl, or two R^5 groups together form a 5- or 6-membered heterocyclyl ring;

R^{5a} is selected from the group consisting of $C_6\text{-}C_{20}$ aryl and $C_1\text{-}C_{20}$ heteroaryl;

where the asterisk * indicates the attachment site of L, and where one of R^1, R^2, R^3 and R^4 is attached to L;

L is the linker selected from the group consisting of:

$-C(=O)-(PEG)-$;

$-C(=O)-(PEG)-C(=O)-$;

$-C(=O)-(PEG)-O-$;

$-C(=O)-(PEG)-C(=O)N(R^5)-(C_1\text{-}C_{12}$ alkyldiyl$)-$;

$-C(=O)-(PEG)-C(=O)N(R^5)-(C_1\text{-}C_{12}$ alkyldiyl$)-N(R^5)C(=O)-(C_2\text{-}C_5$ monoheterocyclyldiyl$)-$;

$-C(=O)-(PEG)-C(=O)N(R^5)-(C_1\text{-}C_{12}$ alkyldiyl$)-$(MCgluc)$-$;

−C(=O)−(PEG)−C(=O)−(MCgluc)−;

−C(=O)−(PEG)−N(R^5)−;

−C(=O)−(PEG)−SS−(C_1-C_{12} alkyldiyl)−OC(=O)−;


−C(=O)−(PEG)−SS−(C_1-C_{12} alkyldiyl)−C(=O)−;


−C(=O)−$CH_2CH_2OCH_2CH_2$−(C_1-C_{20} heteroaryldiyl)−CH_2O−(PEG)−C(=O)−(MCgluc)−; and


−C(=O)−$CH_2CH_2OCH_2CH_2$−(C_1-C_{20} heteroaryldiyl)−CH_2O−(PEG)−C(=O)−(MCgluc)−N(R^5)−(C_1-C_{12} alkyldiyl)−N(R^5)C(=O)−(C_2-C_5 monoheterocyclyldiyl)−; and

PEG has the formula: $-(CH_2CH_2O)_n-(CH_2)_m-$; m is an integer from 1 to 5, and n is an integer from 5 to 50;

MCgluc is selected from the groups:


;


; and



where q is 1 to 8, and AA is an amino acid side chain; and

alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are independently and optionally substituted with one or more groups independently selected from F, Cl, Br, I, –CN, $–CH_3$, $–CH_2CH_3$, $–CH{=}CH_2$, $–C{\equiv}CH$, $–C{\equiv}CCH_3$, $–CH_2CH_2CH_3$, $–CH(CH_3)_2$, $–CH_2CH(CH_3)_2$, $–CH_2OH$, $–CH_2OCH_3$, $–CH_2CH_2OH$, $–C(CH_3)_2OH$, $–CH(OH)CH(CH_3)_2$, $–C(CH_3)_2CH_2OH$, $–CH_2CH_2SO_2CH_3$, $–CH_2OP(O)(OH)_2$, $–CH_2F$, $–CHF_2$, $–CF_3$, $–CH_2CF_3$, $–CH_2CHF_2$, $–CH(CH_3)CN$, $–C(CH_3)_2CN$, $–CH_2CN$, $–CH_2NH_2$, $–CH_2NHSO_2CH_3$, $–CH_2NHCH_3$, $–CH_2N(CH_3)_2$, $–CO_2H$, $–COCH_3$, $–CO_2CH_3$, $–CO_2C(CH_3)_3$, $–COCH(OH)CH_3$, $–CONH_2$, $–CONHCH_3$, $–CON(CH_3)_2$, $–C(CH_3)_2CONH_2$, $–NH_2$, $–NHCH_3$, $–N(CH_3)_2$, $–NHCOCH_3$, $–N(CH_3)COCH_3$, $–NHS(O)_2CH_3$, $–N(CH_3)C(CH_3)_2CONH_2$, $–N(CH_3)CH_2CH_2S(O)_2CH_3$, –NHC(=NH)H, $–NHC(=NH)CH_3$, $–NHC(=NH)NH_2$, $–NHC(=O)NH_2$, $–NO_2$, =O, –OH, $–OCH_3$,

−O−(C_1-C_{12} alkyldiyl)−N(R^5)$_2$;

−O−(C_1-C_{12} alkyldiyl)−N(R^5)−*;

−S(=O)$_2$−(C_2-C_{20} heterocyclyldiyl)−*;

−S(=O)$_2$−(C_2-C_{20} heterocyclyldiyl)−(C_1-C_{12} alkyldiyl)−N(R^5)$_2$;

−S(=O)$_2$−(C_2-C_{20} heterocyclyldiyl)−(C_1-C_{12} alkyldiyl)−NR^5−*; and

−S(=O)$_2$−(C_2-C_{20} heterocyclyldiyl)−(C_1-C_{12} alkyldiyl)−OH;

or R^2 and R^3 together form a 5- or 6-membered heterocyclyl ring;

X^1, X^2, X^3, and X^4 are independently selected from the group consisting of a bond, C(=O), C(=O)N(R^5), O, N(R^5), S, S(O)$_2$, and S(O)$_2$N(R^5);

R^5 is selected from the group consisting of H, C_6-C_{20} aryl, C_6-C_{20} aryldiyl, C_1-C_{12} alkyl, and C_1-C_{12} alkyldiyl, or two R^5 groups together form a 5- or 6-membered heterocyclyl ring;

R^{5a} is selected from the group consisting of C_6-C_{20} aryl and C_1-C_{20} heteroaryl;

where the asterisk * indicates the attachment site of L, and where one of R^1, R^2, R^3 and R^4 is attached to L;

L is the linker selected from the group consisting of:

Q−C(=O)−(PEG)−;

Q−C(=O)−(PEG)−C(=O)−;

Q−C(=O)−(PEG)−O−;

Q−C(=O)−(PEG)−C(=O)N(R^5)−(C_1-C_{12} alkyldiyl)−;

Q−C(=O)−(PEG)−C(=O)N(R^5)−(C_1-C_{12} alkyldiyl)−N(R^5)C(=O)−(C_2-C_5 monoheterocyclyldiyl)−;

Q−C(=O)−(PEG)−C(=O)N(R^5)−(C_1-C_{12} alkyldiyl)−(MCgluc)−;

Q−C(=O)−(PEG)−C(=O)−(MCgluc)−;

Q−C(=O)−(PEG)−N(R^5)−;

Q−C(=O)−(PEG)−SS−(C_1-C_{12} alkyldiyl)−OC(=O)−;




Q–C(=O)–(PEG)–SS–(C_1-C_{12} alkyldiyl)–C(=O)–;

Q–C(=O)–$CH_2CH_2OCH_2CH_2$–(C_1-C_{20} heteroaryldiyl)–CH_2O–(PEG)–C(=O)–(MCgluc)–;

Q–C(=O)–$CH_2CH_2OCH_2CH_2$–(C_1-C_{20} heteroaryldiyl)–CH_2O–(PEG)–C(=O)–(MCgluc)–N(R^5)–(C_1-C_{12} alkyldiyl)–N(R^5)C(=O)–(C_2-C_5 monoheterocyclyldiyl)–; and

where PEG has the formula:–$(CH_2CH_2O)_n$–$(CH_2)_m$–; m is an integer from 1 to 5, and n is an integer from 5 to 50;

MCgluc is selected from the groups:


;

; and


where q is 1 to 8, and AA is an amino acid side chain; and

Q is selected from the group consisting of N-hydroxysuccinimidyl, N-hydroxysulfosuccinimidyl, and phenoxy substituted with one or more groups independently selected from F, Cl, NO_2, and SO_3^-;

where alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, –CN, –CH_3, –CH_2CH_3, –$CH{=}CH_2$, –C≡CH, –C≡CCH_3, –$CH_2CH_2CH_3$, –$CH(CH_3)_2$, –$CH_2CH(CH_3)_2$, –CH_2OH, –CH_2OCH_3, –CH_2CH_2OH, –$C(CH_3)_2OH$, –$CH(OH)CH(CH_3)_2$, –$C(CH_3)_2CH_2OH$, –$CH_2CH_2SO_2CH_3$, –$CH_2OP(O)(OH)_2$, –CH_2F, –CHF_2, –CF_3, –CH_2CF_3, –CH_2CHF_2, –$CH(CH_3)CN$, –$C(CH_3)_2CN$, –CH_2CN, –CH_2NH_2, –$CH_2NHSO_2CH_3$, –CH_2NHCH_3, –$CH_2N(CH_3)_2$, –CO_2H, –$COCH_3$, –CO_2CH_3, –$CO_2C(CH_3)_3$, –$COCH(OH)CH_3$, –$CONH_2$, –$CONHCH_3$, –$CON(CH_3)_2$, –$C(CH_3)_2CONH_2$, –NH_2, –$NHCH_3$, –$N(CH_3)_2$, –$NHCOCH_3$, –$N(CH_3)COCH_3$, –$NHS(O)_2CH_3$, –$N(CH_3)C(CH_3)_2CONH_2$, –$N(CH_3)CH_2CH_2S(O)_2CH_3$, –NHC(=NH)H, –$NHC(=NH)CH_3$, –$NHC(=NH)NH_2$, –$NHC(=O)NH_2$, –$NO_2$, =O, –OH, –$OCH_3$, –$OCH_2CH_3$, –$OCH_2CH_2OCH_3$, –$OCH_2CH_2OH$, –$OCH_2CH_2N(CH_3)_2$, –$O(CH_2CH_2O)_n$–

CLAIMS:

1. An immunoconjugate comprising an antibody covalently attached to one or more aminobenzazepine moieties by a linker, and having Formula I:

$$Ab–[L–Bza]_p \qquad I$$


or a pharmaceutically acceptable salt thereof,

wherein:

Ab is the antibody;

p is an integer from 1 to 8;

Bza is the aminobenzazepine moiety having the formula:



R^1, R^2, R^3, and R^4 are independently selected from the group consisting of H, C_1-C_{12} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{12} carbocyclyl, C_6-C_{20} aryl, C_2-C_9 heterocyclyl, and C_1-C_{20} heteroaryl, where alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl are independently and optionally substituted with one or more groups selected from:

–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_3-C_{12} carbocyclyl);

–(C_3-C_{12} carbocyclyl)–*;

–(C_3-C_{12} carbocyclyl)–(C_1-C_{12} alkyldiyl)–NR^5–*;

–(C_3-C_{12} carbocyclyl)–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_3-C_{12} carbocyclyl)–NR^5–C(=NR^5)NR^5–*;

–(C_6-C_{20} aryl);

–(C_6-C_{20} aryl)–*;

–(C_6-C_{20} aryldiyl)–N(R^5)–*;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–NR^5–C(=NR^{5a})N(R^5)–*;

–(C_2-C_{20} heterocyclyl);

–(C_2-C_{20} heterocyclyl)–*;

–(C_2-C_9 heterocyclyl)–(C_1-C_{12} alkyldiyl)–NR^5–*;

–(C_2-C_9 heterocyclyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–(C_2-C_9 heterocyclyl)–NR^5–$C(=NR^{5a})NR^5$–*;

–(C_1-C_{20} heteroaryl);

–(C_1-C_{20} heteroaryl)–*;

–(C_1-C_{20} heteroaryl)–(C_1-C_{12} alkyldiyl)–$N(R^5)$–*;

–(C_1-C_{20} heteroaryl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–(C_1-C_{20} heteroaryl)–NR^5–$C(=NR^{5a})N(R^5)$–*;

–C(=O)–*;

–C(=O)–(C_2-C_{20} heterocyclyldiyl)–*;

–$C(=O)N(R^5)_2$;

–$C(=O)N(R^5)$–*;

–$C(=O)N(R^5)$–(C_1-C_{12} alkyldiyl)–$N(R^5)C(=O)R^5$;

–$C(=O)N(R^5)$–(C_1-C_{12} alkyldiyl)–$N(R^5)C(=O)N(R^5)_2$;

–$C(=O)NR^5$–(C_1-C_{12} alkyldiyl)–$N(R^5)CO_2R^5$;

–$C(=O)NR^5$–(C_1-C_{12} alkyldiyl)–$N(R^5)C(=NR^{5a})N(R^5)_2$;

–$C(=O)NR^5$–(C_1-C_{12} alkyldiyl)–$NR^5C(=NR^{5a})R^5$;

–$C(=O)NR^5$–(C_1-C_8 alkyldiyl)–NR^5(C_2-C_5 heteroaryl);

–$C(=O)NR^5$–(C_1-C_{20} heteroaryldiyl)–$N(R^5)$–*;

–$C(=O)NR^5$–(C_1-C_{20} heteroaryldiyl)–*;

–$C(=O)NR^5$–(C_1-C_{20} heteroaryldiyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–$C(=O)NR^5$–(C_1-C_{20} heteroaryldiyl)–(C_2-C_{20} heterocyclyldiyl)–$C(=O)NR^5$–(C_1-C_{12} alkyldiyl)–NR^5–*;

–$N(R^5)_2$;

–$N(R^5)$–*;

–$N(R^5)C(=O)R^5$;

–$N(R^5)C(=O)$–*;

–$N(R^5)C(=O)N(R^5)_2$;

–$N(R^5)C(=O)N(R^5)$–*;

–$N(R^5)CO_2R^5$;

–$NR^5C(=NR^{5a})N(R^5)_2$;

–$NR^5C(=NR^{5a})N(R^5)$–*;

–$NR^5C(=NR^{5a})R^5$;

–$N(R^5)$–(C_2-C_5 heteroaryl);

–O–(C_1-C_{12} alkyl);

–O–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–O–(C_1-C_{12} alkyldiyl)–$N(R^5)$–*;

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–*;

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–(C_1-C_{12} alkyldiyl)–NR^5–*; and

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–(C_1-C_{12} alkyldiyl)–OH;

or R^2 and R^3 together form a 5- or 6-membered heterocyclyl ring;

X^1, X^2, X^3, and X^4 are independently selected from the group consisting of a bond, C(=O), C(=O)$N(R^5)$, O, $N(R^5)$, S, $S(O)_2$, and $S(O)_2N(R^5)$;

R^5 is selected from the group consisting of H, C_6-C_{20} aryl, C_6-C_{20} aryldiyl, C_1-C_{12} alkyl, and C_1-C_{12} alkyldiyl, or two R^5 groups together form a 5- or 6-membered heterocyclyl ring;

R^{5a} is selected from the group consisting of C_6-C_{20} aryl and C_1-C_{20} heteroaryl;

where the asterisk * indicates the attachment site of L, and where one of R^1, R^2, R^3 and R^4 is attached to L;

L is the linker selected from the group consisting of:

–C(=O)–(PEG)–;

–C(=O)–(PEG)–C(=O)–;

–C(=O)–(PEG)–O–;

–C(=O)–(PEG)–C(=O)$N(R^5)$–(C_1-C_{12} alkyldiyl)–;

–C(=O)–(PEG)–C(=O)$N(R^5)$–(C_1-C_{12} alkyldiyl)–$N(R^5)$C(=O)–(C_2-C_5 monoheterocyclyldiyl)–;

–C(=O)–(PEG)–C(=O)$N(R^5)$–(C_1-C_{12} alkyldiyl)–(MCgluc)–;

–C(=O)–(PEG)–C(=O)–(MCgluc)–;

–C(=O)–(PEG)–$N(R^5)$–;

–C(=O)–(PEG)–SS–(C_1-C_{12} alkyldiyl)–OC(=O)–;


–C(=O)–(PEG)–SS–(C_1-C_{12} alkyldiyl)–C(=O)–;

–C(=O)–$CH_2CH_2OCH_2CH_2$–(C_1-C_{20} heteroaryldiyl)–CH_2O–(PEG)–C(=O)–(MCgluc)–; and


–C(=O)–$CH_2CH_2OCH_2CH_2$–(C_1-C_{20} heteroaryldiyl)–CH_2O–(PEG)–C(=O)–(MCgluc)–N(R^5)–(C_1-C_{12} alkyldiyl)–N(R^5)C(=O)–(C_2-C_5 monoheterocyclyldiyl)–; and

PEG has the formula: –$(CH_2CH_2O)_n$–$(CH_2)_m$–; m is an integer from 1 to 5, and n is an integer from 5 to 50;


MCgluc is selected from the groups:



;



; and



where q is 1 to 8, and AA is an amino acid side chain; and


alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are independently and optionally substituted with one or more groups independently selected from F, Cl, Br, I, –CN, $–CH_3$, $–CH_2CH_3$, $–CH=CH_2$, –C≡CH, $–C≡CCH_3$, $–CH_2CH_2CH_3$, $–CH(CH_3)_2$, $–CH_2CH(CH_3)_2$, $–CH_2OH$, $–CH_2OCH_3$, $–CH_2CH_2OH$, $–C(CH_3)_2OH$, $–CH(OH)CH(CH_3)_2$, $–C(CH_3)_2CH_2OH$, $–CH_2CH_2SO_2CH_3$, $–CH_2OP(O)(OH)_2$, $–CH_2F$, $–CHF_2$, $–CF_3$, $–CH_2CF_3$, $–CH_2CHF_2$, $–CH(CH_3)CN$, $–C(CH_3)_2CN$, $–CH_2CN$, $–CH_2NH_2$, $–CH_2NHSO_2CH_3$, $–CH_2NHCH_3$, $–CH_2N(CH_3)_2$, $–CO_2H$, $–COCH_3$, $–CO_2CH_3$, $–CO_2C(CH_3)_3$, $–COCH(OH)CH_3$, $–CONH_2$, $–CONHCH_3$, $–CON(CH_3)_2$, $–C(CH_3)_2CONH_2$, $–NH_2$, $–NHCH_3$, $–N(CH_3)_2$, $–NHCOCH_3$, $–N(CH_3)COCH_3$, $–NHS(O)_2CH_3$, $–N(CH_3)C(CH_3)_2CONH_2$, $–N(CH_3)CH_2CH_2S(O)_2CH_3$, –NHC(=NH)H, $–NHC(=NH)CH_3$, $–NHC(=NH)NH_2$, $–NHC(=O)NH_2$, $–NO_2$, =O, –OH, $–OCH_3$, $–OCH_2CH_3$, $–OCH_2CH_2OCH_3$, $–OCH_2CH_2OH$, $–OCH_2CH_2N(CH_3)_2$, $–O(CH_2CH_2O)_n$–

$(CH_2)_mCO_2H$, $-O(CH_2CH_2O)_nH$, $-OP(O)(OH)_2$, $-S(O)_2N(CH_3)_2$, $-SCH_3$, $-S(O)_2CH_3$, and $-S(O)_3H$.


2. The immunoconjugate of claim 1 wherein the antibody is an antibody construct that has an antigen binding domain that binds a target selected from PD-L1, HER2, and CEA.

3. The immunoconjugate of claim 2 wherein the antibody is selected from the group consisting of atezolizumab, durvalumab, avelumab, trastuzumab, pertuzumab, and labetuzumab.


4. The immunoconjugate of any one of claims 1 to 3 wherein Bza is selected from Formulas Ia-h:




Ia




Ib




Ic



Id




Ie




If

where R^{5a} of Formula If is selected from the group consisting of phenyl and pyridyl, optionally substituted with one or more groups selected from F, Cl, Br, I, $-CN$, $-NO_2$ and $-OCH_3$;



Ig



Ih .

5. The immunoconjugate of claim 4 wherein L is –C(=O)–(PEG)– or –C(=O)–(PEG)–C(=O)–.


6. The immunoconjugate of claim 5 wherein R^2 and R^3 are each C_1-C_8 alkyl.

7. The immunoconjugate of claim 6 wherein R^2 and R^3 are each $–CH_2CH_2CH_3$.

8. The immunoconjugate of claim 1 wherein X^2 is O, and R^2 is C_1-C_{12} alkyl.

9. The immunoconjugate of claim 8 wherein R^2 is $–CH_2CH_3$.

10. An aminobenzazepine-linker compound of Formula II:



II

wherein

Z is selected from H, –O(C_1-C_8 alkyl), and N(X^2R^2)(X^3R^3);

R^1, R^2, R^3, and R^4 are independently selected from the group consisting of H, C_1-C_{12} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{12} carbocyclyl, C_6-C_{20} aryl, C_2-C_9 heterocyclyl, and C_1-C_{20} heteroaryl, where alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl are independently and optionally substituted with one or more groups selected from:

–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_3-C_{12} carbocyclyl);

–(C_3-C_{12} carbocyclyl)–*;

–(C_3-C_{12} carbocyclyl)–(C_1-C_{12} alkyldiyl)–NR^5–*;

–(C_3-C_{12} carbocyclyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–(C_3-C_{12} carbocyclyl)–NR^5–$C(=NR^5)NR^5$–*;

–(C_6-C_{20} aryl);

–(C_6-C_{20} aryl)–*;

–(C_6-C_{20} aryldiyl)–$N(R^5)$–*;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)$–*;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–NR^5–$C(=NR^{5a})N(R^5)$–*;

–(C_2-C_{20} heterocyclyl);

–(C_2-C_{20} heterocyclyl)–*;

–(C_2-C_9 heterocyclyl)–(C_1-C_{12} alkyldiyl)–NR^5–*;

–(C_2-C_9 heterocyclyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–(C_2-C_9 heterocyclyl)–NR^5–$C(=NR^{5a})NR^5$–*;

–(C_1-C_{20} heteroaryl);

–(C_1-C_{20} heteroaryl)–*;

–(C_1-C_{20} heteroaryl)–(C_1-C_{12} alkyldiyl)–$N(R^5)$–*;

–(C_1-C_{20} heteroaryl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–(C_1-C_{20} heteroaryl)–NR^5–$C(=NR^{5a})N(R^5)$–*;

–C(=O)–*;

–C(=O)–(C_2-C_{20} heterocyclyldiyl)–*;

–$C(=O)N(R^5)_2$;

–$C(=O)N(R^5)$–*;

–$C(=O)N(R^5)$–(C_1-C_{12} alkyldiyl)–$N(R^5)C(=O)R^5$;

–$C(=O)N(R^5)$–(C_1-C_{12} alkyldiyl)–$N(R^5)C(=O)N(R^5)_2$;

–$C(=O)NR^5$–(C_1-C_{12} alkyldiyl)–$N(R^5)CO_2R^5$;

–$C(=O)NR^5$–(C_1-C_{12} alkyldiyl)–$N(R^5)C(=NR^{5a})N(R^5)_2$;

–$C(=O)NR^5$–(C_1-C_{12} alkyldiyl)–$NR^5C(=NR^{5a})R^5$;

–$C(=O)NR^5$–(C_1-C_8 alkyldiyl)–NR^5(C_2-C_5 heteroaryl);

–$C(=O)NR^5$–(C_1-C_{20} heteroaryldiyl)–$N(R^5)$–*;

–$C(=O)NR^5$–(C_1-C_{20} heteroaryldiyl)–*;

–$C(=O)NR^5$–(C_1-C_{20} heteroaryldiyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–C(=O)NR^5–(C_1-C_{20} heteroaryldiyl)–(C_2-C_{20} heterocyclyldiyl)–C(=O)NR^5–(C_1-C_{12} alkyldiyl)–NR^5–*;

–$N(R^5)_2$;

–$N(R^5)$–*;

–$N(R^5)C(=O)R^5$;

–$N(R^5)C(=O)$–*;

–$N(R^5)C(=O)N(R^5)_2$;

–$N(R^5)C(=O)N(R^5)$–*;

–$N(R^5)CO_2R^5$;

–$NR^5C(=NR^{5a})N(R^5)_2$;

–$NR^5C(=NR^{5a})N(R^5)$–*;

–$NR^5C(=NR^{5a})R^5$;

–$N(R^5)$–(C_2-C_5 heteroaryl);

–O–(C_1-C_{12} alkyl);

–O–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–O–(C_1-C_{12} alkyldiyl)–$N(R^5)$–*;

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–*;

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–(C_1-C_{12} alkyldiyl)–$N(R^5)_2$;

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–(C_1-C_{12} alkyldiyl)–NR^5–*; and

–$S(=O)_2$–(C_2-C_{20} heterocyclyldiyl)–(C_1-C_{12} alkyldiyl)–OH;

or R^2 and R^3 together form a 5- or 6-membered heterocyclyl ring;

X^1, X^2, X^3, and X^4 are independently selected from the group consisting of a bond, C(=O), C(=O)$N(R^5)$, O, $N(R^5)$, S, $S(O)_2$, and $S(O)_2N(R^5)$;

R^5 is selected from the group consisting of H, C_6-C_{20} aryl, C_6-C_{20} aryldiyl, C_1-C_{12} alkyl, and C_1-C_{12} alkyldiyl, or two R^5 groups together form a 5- or 6-membered heterocyclyl ring;

R^{5a} is selected from the group consisting of C_6-C_{20} aryl and C_1-C_{20} heteroaryl;

where the asterisk * indicates the attachment site of L, and where one of R^1, R^2, R^3 and R^4 is attached to L;

L is the linker selected from the group consisting of:

Q–C(=O)–(PEG)–;

Q–C(=O)–(PEG)–C(=O)–;

Q–C(=O)–(PEG)–O–;

Q–C(=O)–(PEG)–C(=O)$N(R^5)$–(C_1-C_{12} alkyldiyl)–;

Q–C(=O)–(PEG)–C(=O)N(R^5)–(C_1-C_{12} alkyldiyl)–N(R^5)C(=O)–(C_2-C_5 monoheterocyclyldiyl)–;

Q–C(=O)–(PEG)–C(=O)N(R^5)–(C_1-C_{12} alkyldiyl)–(MCgluc)–;

Q–C(=O)–(PEG)–C(=O)–(MCgluc)–;

Q–C(=O)–(PEG)–N(R^5)–;

Q–C(=O)–(PEG)–SS–(C_1-C_{12} alkyldiyl)–OC(=O)–;


Q–C(=O)–(PEG)–SS–(C_1-C_{12} alkyldiyl)–C(=O)–;

Q–C(=O)–$CH_2CH_2OCH_2CH_2$–(C_1-C_{20} heteroaryldiyl)–CH_2O–(PEG)–C(=O)–(MCgluc)–;


Q–C(=O)–$CH_2CH_2OCH_2CH_2$–(C_1-C_{20} heteroaryldiyl)–CH_2O–(PEG)–C(=O)–(MCgluc)–N(R^5)–(C_1-C_{12} alkyldiyl)–N(R^5)C(=O)–(C_2-C_5 monoheterocyclyldiyl)–; and

where PEG has the formula:–$(CH_2CH_2O)_n$–$(CH_2)_m$–; m is an integer from 1 to 5, and n is an integer from 5 to 50;


MCgluc is selected from the groups:



;



; and




where q is 1 to 8, and AA is an amino acid side chain; and


Q is selected from the group consisting of N-hydroxysuccinimidyl, N-hydroxysulfosuccinimidyl, and phenoxy substituted with one or more groups independently selected from F, Cl, NO_2, and SO_3^-;

where alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, –CN, –CH_3, –CH_2CH_3, –$CH{=}CH_2$, –C≡CH, –C≡CCH_3, –$CH_2CH_2CH_3$, –$CH(CH_3)_2$, –$CH_2CH(CH_3)_2$, –CH_2OH, –CH_2OCH_3, –CH_2CH_2OH, –$C(CH_3)_2OH$, –$CH(OH)CH(CH_3)_2$, –$C(CH_3)_2CH_2OH$, –$CH_2CH_2SO_2CH_3$, –$CH_2OP(O)(OH)_2$, –CH_2F, –CHF_2, –CF_3, –CH_2CF_3, –CH_2CHF_2, –$CH(CH_3)CN$, –$C(CH_3)_2CN$, –CH_2CN, –CH_2NH_2, –$CH_2NHSO_2CH_3$, –CH_2NHCH_3, –$CH_2N(CH_3)_2$, –CO_2H, –$COCH_3$, –CO_2CH_3, –$CO_2C(CH_3)_3$, –$COCH(OH)CH_3$, –$CONH_2$, –$CONHCH_3$, –$CON(CH_3)_2$, –$C(CH_3)_2CONH_2$, –NH_2, –$NHCH_3$, –$N(CH_3)_2$, –$NHCOCH_3$, –$N(CH_3)COCH_3$, –$NHS(O)_2CH_3$, –$N(CH_3)C(CH_3)_2CONH_2$, –$N(CH_3)CH_2CH_2S(O)_2CH_3$, –NHC(=NH)H, –$NHC(=NH)CH_3$, –$NHC(=NH)NH_2$, –$NHC(=O)NH_2$, –$NO_2$, =O, –OH, –$OCH_3$, –$OCH_2CH_3$, –$OCH_2CH_2OCH_3$, –$OCH_2CH_2OH$, –$OCH_2CH_2N(CH_3)_2$, –$O(CH_2CH_2O)_n$–$(CH_2)_mCO_2H$, –$O(CH_2CH_2O)_nH$, –$OP(O)(OH)_2$, –$S(O)_2N(CH_3)_2$, –$SCH_3$, –$S(O)_2CH_3$, and –$S(O)_3H$.


11. The aminobenzazepine-linker compound of claim 10 selected from Formulas IIa-h:




IIa




IIb




IIc



IId




IIe




IIf

where R^{5a} of Formula If is selected from the group consisting of phenyl and pyridyl, optionally substituted with one or more groups selected from F, Cl, Br, I, –CN, $–NO_2$ and $–OCH_3$;



IIg



IIh .


12. The aminobenzazepine-linker compound of any one of claims 10 to 11 wherein R^2 and R^3 are each C_1-C_8 alkyl.

13. The aminobenzazepine-linker compound of claim 12 wherein R^2 and R^3 are each $-CH_2CH_2CH_3$.

14. The aminobenzazepine-linker compound of claim 13 wherein X^2 is O, and R^2 is C_1-C_{12} alkyl.

15. The aminobenzazepine-linker compound of claim 14 wherein R^2 is $-CH_2CH_3$.


16. The aminobenzazepine-linker compound of claim 10 wherein Q is selected from:





, and


.


17. The aminobenzazepine-linker compound of claim 10 selected from




























































































































































































18. An immunoconjugate prepared by conjugation of an antibody with an aminobenzazepine-linker compound of claim 17.

19. A pharmaceutical composition comprising a therapeutically effective amount of an immunoconjugate according to any one of claims 1-9 and one or more pharmaceutically acceptable diluent, vehicle, carrier or excipient.

20. Use of an immunoconjugate according to any one of claims 1-9 for treating cancer, wherein the cancer is selected from bladder cancer, urinary tract cancer, urothelial carcinoma, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, and breast cancer.

21. A method of preparing an immunoconjugate of Formula I of claim 1 wherein an aminobenzazepine-linker compound of Formula II of claim 10 is conjugated with the antibody.